The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Highlights in gastric cancer from ESMO 2021
Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses important studies in the field of gastric cancer presented at the the European Society for Medical Oncology (ESMO) 2021 congress. Firstly, the two-year follow-up of the CheckMate 649 trial (NCT02872116) indicated a long-term survival benefit for patients with advanced metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma treated with nivolumab and chemotherapy in comparison to patients treated with chemotherapy alone. In addition, it was shown that patients treated with ipilimumab and nivolumab did not experience a benefit in overall survival (OS) in comparison to patients treated with chemotherapy. This supports nivolumab plus chemotherapy as the best first-line treatment for this patient population. Secondly, the KRYSTAL-1 study (NCT03785249) evaluating the KRAS G12C inhibitor adagrasib in combination with cetuximab in patients with metastatic colorectal cancer demonstrated promising preliminary results in terms of efficacy. Thirdly, the DESTINY-Gastric02 study (NCT04014075) assessing the efficacy of trastuzumab deruxtecan (T-DXd) in European patients with upper gastrointestinal tumors who have progressed on trastuzumab treatment showed improvements in terms of overall response rate (ORR) and progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
